Aptinyx's Chronic Pain Candidate Fails To Top Placebo In Mid-Stage Study

Aptinyx Inc APTX has announced results from a Phase 2b study evaluating the effects of NYX-2925 in patients with fibromyalgia, characterized by muscular or musculoskeletal pain with stiffness and localized tenderness at specific points.
NYX-2925 did not achieve statistically significant separation from placebo on the study's primary endpoint of change in average daily pain.
"We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients," said Andy Kidd, president & CEO.
Related: Aptinyx Shares Tank On Disappointed Data From Mid-Stage Diabetic Peripheral Neuropathy Study.
The company continues to analyze the data from the study. It will focus the resources on supporting the readout of the Phase 2 study of NYX-458 in cognitive impairment associated with Parkinson's disease, expected in Q1 of 2023.
Patients receiving NYX-2925 at both dose levels showed a trend toward clinically meaningful improvement in pain and some secondary endpoints versus placebo by week 4.
However, by week 12, the placebo group had improved such that, although NYX-2925 remained numerically better, the separation was not clinically meaningful.
Across both dose levels, NYX-2925 was well tolerated in the study, with no concerning safety issues observed.
Price Action: APTX shares are down 33.30% at $0.40 on the last check Friday.